Edition:
United Kingdom

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

9.05USD
16 Aug 2018
Change (% chg)

$0.47 (+5.48%)
Prev Close
$8.58
Open
$8.58
Day's High
$9.07
Day's Low
$8.41
Volume
31,343
Avg. Vol
76,787
52-wk High
$23.68
52-wk Low
$5.92

Chart for

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing... (more)

Overall

Beta: --
Market Cap(Mil.): $317.10
Shares Outstanding(Mil.): 16.90
Dividend: --
Yield (%): --

Financials

  PTGX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -3.00 -- --
ROI: -116.32 1.78 14.61
ROE: -643.53 3.28 16.33

BRIEF-Protagonist Therapeutics Reports Q1 Net Loss Per Share $0.36

* PROTAGONIST THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100

* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS

26 Mar 2018

BRIEF-Protagonist Therapeutics Q4 Loss Per Share $0.15

* PROTAGONIST THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

07 Mar 2018

BRIEF-FDA Grants Orphan Drug Designation For Protagonist Therapeutics' PTG-300

* FDA GRANTS ORPHAN DRUG DESIGNATION FOR PROTAGONIST THERAPEUTICS' PTG-300 FOR THE TREATMENT OF BETA-THALASSEMIA Source text for Eikon: Further company coverage:

06 Mar 2018

Earnings vs. Estimates